Abstracts tagged "clinical trial"

Abstract Number: 0900 • ACR Convergence 2020
Achievement of Low Disease Activity According to BASDAI with Ixekizumab in Patients with Axial Spondyloarthritis: 16-Week Results from the COAST Trials
Denis Poddubnyy¹, Xavier Juanola², Clément Prati³, Hagen Russ⁴, Yves Schymura⁴, Soyi Liu-Leage⁵, Mani Haschemi Nassab⁴ and Jean Dudler⁶, ¹Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Rheumatology Service, University Hospital Bellvitge, IDIBELL, Barcelona, Spain, Barcelona, Spain, ³Service de Rhumatologie, Hôpital Jean-Minjoz , Besançon, France, Besançon, France, ⁴Eli Lilly and Company, Indianapolis, Indiana, USA, Indianapolis, IN, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Rheumatology, HFR Fribourg - Hospital Cantonal, Fribourg, Switzerland, Fribourg, Switzerland
Background/Purpose: The efficacy of ixekizumab (IXE), a selective interleukin-17A antagonist, was assessed in patients (pts) with axial SpA (axSpA) in three Phase 3, randomized, double-blind,…
Abstract Number: 1231 • ACR Convergence 2020
Radiographic Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib as Monotherapy or in Combination with Methotrexate: Results at 2 Years
Charles Peterfy¹, Vibeke Strand², Mark Genovese³, Alan Friedman⁴, Jeffrey Enejosa⁴, Stephen Hall⁵, Eduardo Mysler⁶, Patrick Durez⁷, Xenofon Baraliakos⁸, Tim Shaw⁴, Yanna Song⁹, Yihan Li⁴ and In-Ho Song⁴, ¹Spire Sciences, Inc., Boca Raton, FL, ²Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ³Stanford University Medical Center, Palo Alto, CA, ⁴AbbVie Inc., North Chicago, IL, ⁵Cabrini Medical Centre, Monash University and Emeritus Research, Malvern, Victoria, Australia, ⁶Organización Medica de Investigación, Buenos Aires, Argentina, ⁷Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ⁸Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, ⁹AbbVie Inc., North Chicago,, IL
Background/Purpose: For patients with rheumatoid arthritis (RA), long‑term prevention of structural joint damage is a key treatment goal.1 In the SELECT-EARLY and SELECT-COMPARE trials, upadacitinib…
Abstract Number: 1744 • ACR Convergence 2020
The STAtins to Prevent Rheumatoid Arthritis (STAPRA) Trial: Clinical Results and Subsequent Qualitative Study, a Mixed Method Evaluation
Laurette van Boheemen¹, Marieke ter Wee², Samina Turk³, Marian van Beers³, Wouter Bos³, Diane Marsman⁴, Ed Griep⁵, Mirian Starmans⁶, Calin Popa⁷, Alper van Sijl³, Bart Seppen³, Maarten Boers⁸, Mike Nurmohamed⁹ and Dirkjan van Schaardenburg⁸, ¹Amsterdam Rheumatology and immunology Center | Reade, Amste, Netherlands, ²Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ⁴Sint Maartenskliniek, Nijmegen, Netherlands, ⁵Antonius Ziekenhuis, Sneek, Netherlands, ⁶Zuyderland MC, Heerlen, Netherlands, ⁷Radboudumc, Nijmegen, Netherlands, ⁸Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands, ⁹Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands
Background/Purpose: Persons at high risk of developing rheumatoid arthritis (RA) may benefit from a low-risk pharmacological intervention aimed at primary prevention. Previous studies demonstrated disease-modifying…
Abstract Number: 2028 • ACR Convergence 2020
Predictors of Maintaining Inactive Disease After Etanercept Withdrawal, and Regaining Inactive Disease Status After Flare and Retreatment, in Adults with Non-radiographic Axial Spondyloarthritis: Results from RE-EMBARK
Filip Van den Bosch¹, James Cheng-Chung Wei², Francisco Blanco³, Pamela Selema⁴, Daniela Graham⁵, Edmund Arthur⁶, Vassilis Tsekouras⁷, Bonnie Vlahos⁴, Chuanbo Zang⁴, Atul Deodhar⁸ and Peter Nash⁹, ¹Ghent University Hospital, Ghent, Belgium, ²Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), ³INIBIC-Complejo Hospitalario Universitario A Coruña, A Coruna, Spain, ⁴Pfizer, Collegeville, PA, ⁵Pfizer, Groton, PA, ⁶Pfizer, Peapack, NJ, ⁷Pfizer, Nicosia, Cyprus, ⁸Oregon Health & Science University, Portland, OR, ⁹School of Medicine Griffith University, Brisbane, Queensland, Australia
Background/Purpose: RE-EMBARK was a phase 4, multicenter, open-label, 3-period study that evaluated etanercept (ETN) withdrawal and retreatment in adult patients with non-radiographic axial spondyloarthritis (nr-axSpA)…
Abstract Number: 0048 • ACR Convergence 2020
Determinants of Participation in Clinical Trials Among Patients with Lupus in the United States
Onengiya Harry¹, Carl Langefeld², Miranda Marion³, Trent Younts³, Lori Crosby⁴, Mara Vitolins³ and Avani Modi⁴, ¹Wake Forest School of Medicine, Clemmons, NC, ²Wake Forest School of Medicine, Winston Salem, NC, ³Wake Forest School of Medicine, Winston-Salem, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati
Background/Purpose: Patient and family participation in research is critical to improving health outcomes, and identifying factors that contribute to participation or lack of participation in…
Abstract Number: 0214 • ACR Convergence 2020
Sustainability of Response Between Upadacitinib and Adalimumab Among Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
Peter Nash¹, Arthur Kavanaugh², Maya Buch³, Bernard Combe⁴, Louis Bessette⁵, In-Ho Song⁶, Yanna Song⁷, Jessica Suboticki⁶ and Roy Fleischmann⁸, ¹School of Medicine Griffith University, Brisbane, Queensland, Australia, ²Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ³Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, ⁴University of Montpellier, Montpellier, France, ⁵Laval University, Quebec, Canada, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., North Chicago,, IL, ⁸Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: The primary treatment goal for patients(pts) with rheumatoid arthritis(RA) is a state of sustained clinical remission(REM) or low disease activity(LDA).1,2 We assess long-term sustainability…
Abstract Number: 0384 • ACR Convergence 2020
Serum Neutrophil Count Predicts Progression of Interstitial Lung Disease and Mortality in Patients with Systemic Sclerosis Related Interstitial Lung Disease
Nancy Wareing¹, Ning Li², Elizabeth Volkmann³, Marka Lyons⁴, Michael Roth², Donald Tashkin² and Shervin Assassi¹, ¹University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ²University of California, Los Angeles, Los Angeles, ³University of California, Los Angeles, Los Angeles, CA, ⁴University of Texas Houston, McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX
Background/Purpose: Systemic sclerosis (SSc) patients have a prominent neutrophil gene expression signature. However, investigations into the pathophysiologic role of neutrophils in SSc are lacking. This…
Abstract Number: 0798 • ACR Convergence 2020
A Randomized, Double-blind Phase 3 Study Comparing the Efficacy, Safety and Immunogenicity of PF-06410293 (Abrilada™), an Adalimumab (ADL) Biosimilar, and Reference ADL (Humira®) in Patients with Moderate to Severe Active RA: Results from Weeks 52-92
Roy Fleischmann¹, Daniel Alvarez², Amy Bock³, Carol Cronenberger⁴, Ivana Vranic⁵, Wuyan Zhang⁶ and Rieke Alten⁷, ¹Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²Pfizer, Collegeville, PA, ³Pfizer, Cambridge, MA, ⁴Pfizer, Collegeville, ⁵Pfizer, Tadworth, United Kingdom, ⁶Pfizer, New York, ⁷Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany
Background/Purpose: To evaluate the long-term safety, immunogenicity (IG), and efficacy of the adalimumab (ADL) biosimilar, PF-06410293 (ADL-PF), in patients (pts) with moderate to severe active…
Abstract Number: 0935 • ACR Convergence 2020
Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Trial of BIIB059, an Anti-Blood Dendritic Cell Antigen 2 Antibody, in SLE
Richard Furie¹, Ronald van Vollenhoven², Kenneth Kalunian³, Sandra Navarra⁴, Juanita Romero-Díaz⁵, Victoria Werth⁶, Xiaobi Huang⁷, Hua Carroll⁸, Adam Meyers⁷, Cristina Musselli⁷, Catherine Barbey⁹ and Nathalie Franchimont⁷, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ³University of California San Diego, La Jolla, CA, ⁴University of Santo Tomas, Manila, Philippines, ⁵Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁶University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁷Biogen, Cambridge, MA, ⁸Biogen, Cambridge, ⁹Biogen, Baar, Switzerland
Background/Purpose: Type I interferons (IFN-I), inflammatory mediators principally produced by plasmacytoid dendritic cells (pDCs), components of the innate immune system, have been implicated in the…
Abstract Number: 1233 • ACR Convergence 2020
Use of Multi-Biomarker Disease Activity Scores to Compare Biosimilar Adalimumab-afzb (PF-06410293) with EU-Sourced Reference Adalimumab in a Phase 3, Randomized, Double-Blind Trial in Patients with Active RA
Jonathan Kay¹, Amy Bock², Noriko Iikuni³, Wuyan Zhang⁴ and Daniel Alvarez⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Pfizer, Cambridge, MA, ³Pfizer, New York, NY, ⁴Pfizer, New York, ⁵Pfizer, Collegeville, PA
Background/Purpose: Traditional efficacy endpoints of disease activity (DA) in studies of anti-rheumatic drugs can be confounded by subjective (patient-/physician-reported) assessments, comorbidities, and pre-existing joint damage.…
Abstract Number: 1745 • ACR Convergence 2020
A Novel Method for Predicting 1-Year Retention of Abatacept Using Machine Learning Techniques
Rieke Alten¹, Claire Behar², Christine Boileau², Pierre Merckaert², Ebenezer Afari², Virginie Vannier-Moreau³, Sean Connolly³, Yedid Elbez², Pierre-Antoine Juge⁴ and Karissa Lozenski³, ¹Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany, ²Excelya, Boulogne-Billancourt, France, ³Bristol-Myers Squibb Company, Princeton, NJ, ⁴Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France
Background/Purpose: In the ACTION (NCT02109666) study, using multivariable Cox proportional hazards regression models, patient (pt) global assessment of pain, country, reason for stopping last biologic,…
Abstract Number: 2035 • ACR Convergence 2020
Exploring Stratification Strategies for Early Diffuse Systemic Sclerosis Clinical Trial Design
Robyn Domsic¹, Shiyao Gao², Maureen Laffoon², Steven Wisniewski³, Robert Lafyatis⁴, Virginia Steen⁵ and Thomas Medsger⁶, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ⁴University of Pittsburgh, Arlington, MA, ⁵Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁶University of Pittsburgh School of Medicine, Verona, PA
Background/Purpose: Clinical trials in early diffuse systemic sclerosis (SSc) using the modified Rodnan skin score (mRSS) as the primary outcome have been largely negative. This…
Abstract Number: 0107 • ACR Convergence 2020
Effects of Abaloparatide on Modeling and Remodeling Based Bone Formation
David W Dempster¹, Hua Zhou¹, Sudhaker D Rao², Chris Recknor³, Paul D Miller⁴, Benjamin Z Leder⁵, Miriam Annett⁶, Michael S Ominsky⁶ and Bruce H Mitlak⁶, ¹Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, West Haverstraw, NY, ²Bone & Mineral Research Laboratory, Henry Ford Health System, Detroit, MI, Detroit, MI, ³United Osteoporosis Centers, Gainesville, GA, Gainesville, GA, ⁴Colorado Center for Bone Research, Lakewood, CO, Lakewood, CO, ⁵Mass General Hospital, Harvard Medical School, Boston, MA, Boston, MA, ⁶Radius Health, Inc., Waltham, MA, Waltham, MA
Background/Purpose: To evaluate abaloparatide-induced changes in the bone formation indices of mineralizing surface (MS), bone formation rate (BFR) and mineral apposition rate (MAR); and to…
Abstract Number: 0215 • ACR Convergence 2020
Incidence and Risk of Venous Thromboembolic Events Among Patients with Rheumatoid Arthritis Enrolled in the Upadacitinib Clinical Trial Program
Ernest Choy¹, Iain McInnes², John Cush³, Jacob Aelion⁴, William Rigby⁵, Yanna Song⁶, Sebastian Meerwein⁷, John Liu⁸, Nasser Khan⁸, Jessica Suboticki⁸ and Alexander Cohen⁹, ¹CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ²Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³University of Texas Southwestern Medical School, Dallas, TX, ⁴Arthritis Clinic PLLC, Jackson, ⁵Dartmouth College, Norwichi, VT, ⁶AbbVie Inc., North Chicago,, IL, ⁷Pharmaceutical Development, AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ⁸AbbVie Inc., North Chicago, IL, ⁹Guy’s and St Thomas’ NHS FT Hospitals, King’s College, London, United Kingdom
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) are at an increased risk for the development of venous thromboembolism (VTE, including pulmonary embolism [PE] and deep…
Abstract Number: 0385 • ACR Convergence 2020
A Pilot Study to Evaluate the Safety and Efficacy of Treprostinil in the Treatment of Calcinosis in Patients with Systemic Sclerosis
Melody Chung¹, Antonia Maria Valenzuela Vergara², Benjamin Catanese¹, Shufeng Li¹, Kate Stevens¹ and Lorinda Chung³, ¹Stanford University, Stanford, CA, ²Pontificia Universidad Catolica de Chile, Santiago de Chile, Chile, ³Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA
Background/Purpose: Calcinosis is characterized by calcium deposition in skin and subcutaneous tissues and progresses over one year in the majority of systemic sclerosis (SSc) patients. Since…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].